Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

Molecular Cancer Therapeutics

Volumn 6, Issue 3, 2007, Pages 945-956

  Thomas, Huw D ^a   Calabrese, Christopher R ^a   Batey, Michael A ^a   Canan, Stacie ^b   Hostomsky, Zdenek ^b   Kyle, Suzanne ^a   Maegley, Karen A ^b   Newell, David R ^a   Skalitzky, Donald ^b   Wang, Lan Zhen ^a   Webber, Stephen E ^b   Curtin, Nicola J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AG 14361; AG 14418; AG 14451; AG 14452; AG 14477; AG 14521; AG 14531; AG 14584; AG 14598; AG 14644; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIZATION; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DACARBAZINE; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; GAMMA RAYS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MAXIMUM TOLERATED DOSE; MICE; MICE, NUDE; POLY(ADP-RIBOSE) POLYMERASES; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOTECAN;

EID: 34147182310     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0552     Document Type: Article

References (28)

1. Nomura F, Yaguchi M, Togawa A, et al. Enhancement of polyadenosine diphosphate-ribosylation in human hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15:529-35.
2. Hirai K, Ueda K, Hayaishi O. Aberration of poly(adenosine diphosphate ribose) metabolism in human colon adenomatous polys and cancers. Cancer Res 1983;43:3441-6.
3. de Murcia G, Menissier de Murcia J. Poly(ADP-ribose)polymerase: a molecular nick-sensor. Trends Biochem Sci 1994;19:172-6.
4. Lautier D, Lagueux J, Thibodeau J, Menard L, Poirier GG. Molecular and biochemical features of poly(ADP-ribose) metabolism. Mol Cell Biochem 1993;122:171-93.
5. Althaus FR, Hofferer L, Kleczkowska HE, et al. Histone shuttle driven by the automodification cycle of poly(ADP-ribose) polymerase. Environ Mol Mutagen 1993;22:278-82.
6. Dantzer F, Schreiber V, Niedergang C, et al. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 1999;81:69-75.
7. Dantzer F, de la Rubia G, Menissier de Murcia J, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose)polymerase. Biochemistry 2000;39:7559-69.
8. Delaney CA, Wang LZ, Kyle S, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000;6:2860-7.
9. Calabrese CR, Almassy R, Barton S, et al. Preclinical evaluation of a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, AG14361, with significant anticancer chemo- and radio-sensitization activity. J Natl Cancer Inst (Bethesda) 2004;96:56-67.
10. Curtin NJ. PARP inhibitors for cancer therapy. Expert Rev Mol Med 2005;7:1-20.
11. Jagtap P, Szabo C. Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4:421-40.
12. Canan Koch SS, Thoresen LH, Tikhe JG, et al. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray co-crystal structure. J Med Chem 2002;45:4961-74.
13. Skalitzky DJ, Marakovits JT, Maegley KA, et al. Tricyclic benzimidazoles as potent PARP-1 inhibitors. J Med Chem 2003;46:210-3.
14. White AW, Curtin NJ, Eastman BW, et al. Potentiation of cytotoxic drug activity in human tumour cell lines by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorg Med Chem Lett 2004;14:2433-7.
15. Tikhe JG, Webber SE, Hosomsky Z, et al. Design, synthesis, and evaluation of tricyclic inhibitors of poly(ADP-ribose) polymerase. J Med Chem 2004;47:5467-81.
16. Calabrese CR, Batey MA, Thomas HD, et al. Identification of potent non-toxic poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res 2003;9: 2711-8.
17. Marsischky GT, Wilson BA, Collier RJ. Role of glutamic acid 988 of human poly-ADP-ribose polymerase in polymer formation. J Biol Chem 1995;270:3247-54.
18. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity essay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
19. Potter GWH. Analysis of biological molecules: an introduction to principles, instrumentation, and techniques. 1st ed. London: Chapman and Hall; 1995. p. 202.
20. Little JB. Repair of sublethal and potentially lethal radiation damage in plateau phase cultures of human cells. Nature (Lond) 1969;224:804-6.
21. Weichselbaum RR, Little JB. The differential response of human tumours to fractionated radiation may be due to a post-irradiation repair process. Br J Cancer 1982;46:532-7.
22. Wang Z-Q, Auer B, Stingl L, et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 1995;9:509-20.
23. Menissier de Murcia J, Neidergang C, Trucco C. et al. Requirement of poly(ADP-ribode) polymerase in recovery from DNA damage in mice and cells. Proc Natl Acad Sci U S A 1997;94:7303-7.
24. Matsutani M, Nozaki T, Nishiyma E, et al. Function of poly(ADP-ribose) polymerase in mice. Mol Cell Biochem 1999;193:149-52.
25. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, preclinical development, and clinical trials. Cancer Treat Rev 1997;23: 35-61.
26. Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995;55:2853-7.
27. Suggitt M, Bibby MC. 50 Years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 1995; 11:971-81.
28. Kobayashi K, Jodrell DI, Ratain MJ. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. Cancer Surv 1993;17: 51-78.